Neomycin: a specific drug to study the inositol-phospholipid signalling system?
Neomycin, an antibiotic previously thought to interact specifically with inositol-containing phospholipids, was found to inhibit IP3-mediated Ca2+ release from the intracellular stores of permeabilized insulinoma and liver cells. This inhibition could be relieved by increasing the IP3 concentration. Radiolabelled IP3 was found to bind tightly to columns prepared from neomycin covalently attached to glass beads. ATP was also bound by these columns. It is concluded that neomycin acts in biological systems as a weak anion exchanger and is therefore unsuitable for use as a specific tool to study the role of inositol phospholipids in intracellular signalling.
D000818:Animals; D002118:Calcium / Q000378:metabolism*; D002460:Cell Line; D015544:Inositol 1,4,5-Trisphosphate; D007295:Inositol Phosphates / Q000378:metabolism / Q000494:pharmacology*; D007340:Insulinoma / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D009355:Neomycin / Q000378:metabolism / Q000494:pharmacology*; D010190:Pancreatic Neoplasms / Q000378:metabolism; D051381:Rats; D013403:Sugar Phosphates / Q000494:pharmacology*
D007295:Inositol Phosphates; D013403:Sugar Phosphates; D015544:Inositol 1,4,5-Trisphosphate; D009355:Neomycin; D002118:Calcium